Puma Biotechnology received European Commission (EC) marketing authorisation for Nerlynx (neratinib) in breast cancer, despite earlier European Medicines Agency (EMA) efficacy and safety co
European Commission (EC) has approved Pfizer’s Trazimera, for breast and gastric cancer treatment, marking it as pharma’s first oncology biosimilar to receive approval in the EU.
The European Commission (EC) has approved Roche’s Perjeta (pertuzumab) in combination with Herceptin (trastuzumab) and chemotherapy for post-surgery (adjuvant) treatment of adult patients with HER2-positive early breast cancer (eBC) at high risk of recurrence.